The Department of Veterans Affairs National Acquisition Center awarded a single-award Indefinite Delivery Contract (IDC) with a ceiling value of $28,781,200.00 to Exelan Pharmaceuticals Inc., a foreign-owned, for-profit pharmaceutical company based in Boca Raton, Florida. The contract is for the delivery of 6 line items of Prazosin HCL capsules in varying dosages and package sizes to support the VA, Department of Defense, Bureau of Prisons, and Indian Health Service. The base period is one year from February 19, 2023, to February 18, 2024, with four one-year option periods, providing long-term, stable supply arrangements through the VA's and DoD's Pharmaceutical Prime Vendor Programs. Exelan Pharmaceuticals has significant experience as a prime contractor providing a wide range of pharmaceutical products to various federal healthcare agencies, including the VA, DoD, and other customers. The company specializes in manufacturing, distributing, and repackaging pharmaceutical medications, playing a critical role in supporting the healthcare needs of veterans, military personnel, and other federal beneficiaries.
The original solicitation, issued as a pre-solicitation notice, sought an unrestricted procurement for Prazosin HCL capsules with the objective of awarding a single contract that would ensure an uninterrupted source of supply. The estimated annual requirements ranged from 5,518 bottles to 80,000 bottles across six different presentations of the product. The solicitation was issued electronically in a commercial item format in accordance with FAR Part 12, with responses due by September 16, 2022. The National Acquisition Center serves as the funding agency for this contract, which has no set-aside designation.
Generated 1/15/25, 9:09 AM